6533b7dbfe1ef96bd127015d

RESEARCH PRODUCT

Intra-Nasally Administered Oligopeptide Lunasin Acts as a Possible Anti-Psychotic Agent in Mice Models

Zane DzirkaleRuta MucenieceVija KlusaKaspars JekabsonsIlva Nakurte

subject

AgonistMedicine (General)medicine.drug_classreceptor bindingbrain monoaminesPharmacologyMotor ActivityLunasinArticleintranasal administration03 medical and health sciencesMiceR5-9200302 clinical medicinehyper-locomotionmedicineAnimalslunasin; intranasal administration; hyper-locomotion; brain monoamines; receptor bindingAmphetaminePhencyclidine5-HT receptorAdministration IntranasalMice Inbred ICRChemistrylunasinAmphetaminesGeneral MedicineDisease Models AnimalMonoamine neurotransmitter030220 oncology & carcinogenesisNMDA receptorSerotoninOligopeptides030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents

description

Background and Objectives: Previously we have shown that synthetic lunasin, a 43 amino acid residue-containing peptide, after its central (intracisternal) administration in mice demonstrated antagonism against dopaminergic drug behavioural effects, indicating a putative antipsychotic/anti-schizophrenic profile of lunasin. The aims of the present studies were: to test whether lunasin would show an influence on the dopaminergic system after intranasal administration, and to examine the effect(s) of lunasin on serotonin and glutamatergic systems, which could play an essential role in antipsychotic action. Materials and Methods: Lunasin was administered intra-nasally at doses 0.1 and 1 nmol/mouse in ICR mice (n = 7&ndash

yearjournalcountryeditionlanguage
2019-07-21Medicina; Volume 55; Issue 7; Pages: 393
10.3390/medicina55070393https://dx.doi.org/10.3390/medicina55070393